Latest From Biotech Now

“Alz” Well That Ends Well: The Beta-Amyloid Debate in Alzheimer’s Research

alzheimers

Researchers and clinicians alike believe there is substantial evidence to support the hypothesis that Alzheimer’s disease (AD) may be caused by deposition of amyloid beta-peptide (Abeta) in plaques in brain tissue. But drugs targeted towards the beta-amyloid have met with significant setbacks challenging whether the target is, in fact, real. With several late stage drugs targeting beta-amyloid poised for market entry, a panel of opinion leaders in the treatment of Alzheimer’s and scientific industry specialists Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

AUTM Website Helps Commercialize University Technologies

Robin Rasor

By Robin L. Rasor, CLP, RTTP, AUTM President As president of the Association of University Technology Managers (AUTM), I’m in a unique position of hearing from university technology managers who want more opportunity to interact with industry, and industry members who want to identify the latest breakthrough innovations. Industry investors and their academic licensing counterparts already come together for dealmaking at the AUTM Annual Meeting and at the BIO International Convention, but now we have Read More >

Patently BIOtech  |  3 Comments  |  Email This Post
Tags: , , , , , ,

Patent Awards for Humanitarian Ventures

Children

The USPTO recently announced the Patents for Humanity Challenge which awards patent owners and licensees for innovations that address humanitarian needs.  Judges will chose winners from four categories: Medical technology – includes medicines, vaccines, diagnostic equipment, or assistive devices. Food and nutrition – includes agricultural technology like drought-resistant crops, more nutritious crop strains, farming equipment, and technologies that improve food storage, preservation, or preparation. Clean technology – includes technologies that improve public health by removing Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Fireside Chat with Moncef Slaoui, GlaxoSmithKline

Dr. Moncel Slaoui

Moncel Slaoui, chairman of research and development (R&D) at GlaxoSmithKline (GSK), opened the 2012 BIO CEO & Investor Conference with a Fireside Chat where he provided insight in to his company’s biopharma R&D strategy. “GSK has announced that our R&D budget is no more a percentage of sales. If you think about it, it doesn’t make sense,” Slaoui stated, “because, sales are a marker of R&D 10 and 15 years ago.” Right now, GSK has Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Petroleum Refiners Express Contempt for RFS

biofuels-btn

At the National Biodiesel Conference earlier this week, AFPM President Charles Drevna called the Renewable Fuel Standard (RFS) an “anachronism” and claimed that “it’s not working as intended.” Should he be believed? Congress established the RFS with steadily increasing volume mandates for cellulosic biofuels in order to open the petroleum-dominated market to alternatives and spur growth in the industry. Despite the resistance to innovation from the petroleum refiners, that purpose in not an anachronism. Moreover, Read More >

Biofuels & Climate Change  |  Leave a comment  |  Email This Post
Tags: , , , , ,